# A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

> **NCT05473156** · PHASE1,PHASE2 · RECRUITING · sponsor: **AP Biosciences Inc.** · enrollment: 168 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors
- Non Small Cell Lung Cancer (NSCLC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** AP203
- **DRUG:** AP203

## Key facts

- **NCT ID:** NCT05473156
- **Lead sponsor:** AP Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-24
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05473156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05473156, "A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT05473156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*